# A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

Study · id `cardio:ct-nct03361501` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03361501](<https://clinicaltrials.gov/study/NCT03361501>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03361501

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.

## Technical summary

Registry record NCT03361501. Randomized; double masking; primary purpose treatment. Start 2018-02-01 (actual); primary completion 2019-09-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 278 participants (enrolled count; ClinicalTrials.gov record NCT03361501, source copy `cardio:ctgov-nct03361501-2020-08-12`, retrieved 2026-10-31)
- Started: 2018-02-01 (actual) (ClinicalTrials.gov record NCT03361501, source copy `cardio:ctgov-nct03361501-2020-08-12`, retrieved 2026-10-31)
- Primary completion: 2019-09-24 (actual) (ClinicalTrials.gov record NCT03361501, source copy `cardio:ctgov-nct03361501-2020-08-12`, retrieved 2026-10-31)
- Completion: 2020-01-09 (actual) (ClinicalTrials.gov record NCT03361501, source copy `cardio:ctgov-nct03361501-2020-08-12`, retrieved 2026-10-31)
- Countries: United States; Canada; Mexico (ClinicalTrials.gov record NCT03361501, source copy `cardio:ctgov-nct03361501-2020-08-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03361501-2020-08-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
- Acronym: TRILOGY 2
- Condition: Hypertriglyceridemia
- Intervention (Drug): CaPre
- Intervention (Drug): Placebo
- Lead sponsor: Grace Therapeutics Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Grace Therapeutics Inc. (`cardio:org-grace-therapeutics-inc`)

## Provenance

Content hash: 34b4200e24232b45007f4147d2613d13b9c1b43dccf4a40a816adb1820ba4473
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
